Aquestive Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update: AQST-108 and Libervant Remain On Track
Continues to manufacture and deliver therapies and advance R&D efforts during COVID-19 pandemic Expects to submit AQST-108 (epinephrine) IND by June 2020 and to […]